Zacks Investment Research upgraded shares of ProNAi Therapeutics, Inc. (NASDAQ:SRRA) from a sell rating to a hold rating in a research note released on Tuesday morning.

According to Zacks, “Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central regulator of the DNA Damage Response network. SRA141 is an orally available small molecule inhibitor of cell division cycle 7kinase. Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, Inc., is headquatered in Vancouver, Canada. “

Other equities analysts also recently issued reports about the company. Jefferies Group LLC raised ProNAi Therapeutics from a hold rating to a buy rating in a research report on Monday, October 23rd. ValuEngine raised ProNAi Therapeutics from a strong sell rating to a sell rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. ProNAi Therapeutics has a consensus rating of Hold and an average target price of $4.00.

Shares of ProNAi Therapeutics (NASDAQ SRRA) traded up $0.18 during mid-day trading on Tuesday, hitting $2.34. The stock had a trading volume of 1,378,418 shares, compared to its average volume of 340,832. ProNAi Therapeutics has a 1-year low of $1.10 and a 1-year high of $2.44.

ProNAi Therapeutics (NASDAQ:SRRA) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. equities research analysts anticipate that ProNAi Therapeutics will post -0.85 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “ProNAi Therapeutics, Inc. (SRRA) Lifted to Hold at Zacks Investment Research” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/pronai-therapeutics-inc-srra-lifted-to-hold-at-zacks-investment-research/1710412.html.

A hedge fund recently bought a new stake in ProNAi Therapeutics stock. FMR LLC acquired a new stake in shares of ProNAi Therapeutics, Inc. (NASDAQ:SRRA) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 197,100 shares of the biotechnology company’s stock, valued at approximately $302,000. FMR LLC owned about 0.38% of ProNAi Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 55.65% of the company’s stock.

About ProNAi Therapeutics

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Get a free copy of the Zacks research report on ProNAi Therapeutics (SRRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.